Ionis Pharmaceuticals Inc (NASDAQ: IONS) has experienced a decline in its stock price by -3.53 compared to its previous closing price of 33.45. However, the company has seen a fall of -2.06% in its stock price over the last five trading days. zacks.com reported 2025-03-21 that Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What’s next for the stock?
Is It Worth Investing in Ionis Pharmaceuticals Inc (NASDAQ: IONS) Right Now?
The stock has a 36-month beta value of 0.24. Opinions on the stock are mixed, with 13 analysts rating it as a “buy,” 4 as “overweight,” 7 as “hold,” and 0 as “sell.”
The public float for IONS is 154.59M, and at present, short sellers hold a 8.31% of that float. On March 26, 2025, the average trading volume of IONS was 1.61M shares.
IONS’s Market Performance
IONS’s stock has seen a -2.06% decrease for the week, with a 1.19% rise in the past month and a -9.33% fall in the past quarter. The volatility ratio for the week is 3.61%, and the volatility levels for the past 30 days are at 4.31% for Ionis Pharmaceuticals Inc. The simple moving average for the past 20 days is -2.25% for IONS’s stock, with a -18.20% simple moving average for the past 200 days.
Analysts’ Opinion of IONS
Many brokerage firms have already submitted their reports for IONS stocks, with BMO Capital Markets repeating the rating for IONS by listing it as a “Market Perform.” The predicted price for IONS in the upcoming period, according to BMO Capital Markets is $60 based on the research report published on August 02, 2024 of the previous year 2024.
Leerink Partners, on the other hand, stated in their research note that they expect to see IONS reach a price target of $62, previously predicting the price at $53. The rating they have provided for IONS stocks is “Outperform” according to the report published on July 24th, 2024.
Jefferies gave a rating of “Buy” to IONS, setting the target price at $75 in the report published on July 16th of the previous year.
IONS Trading at -1.27% from the 50-Day Moving Average
After a stumble in the market that brought IONS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -38.35% of loss for the given period.
Volatility was left at 4.31%, however, over the last 30 days, the volatility rate increased by 3.61%, as shares surge +1.32% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -3.56% lower at present.
During the last 5 trading sessions, IONS fell by -2.06%, which changed the moving average for the period of 200-days by -19.06% in comparison to the 20-day moving average, which settled at $33.01. In addition, Ionis Pharmaceuticals Inc saw -7.69% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IONS starting from Monia Brett P, who sale 140 shares at the price of $32.32 back on Mar 11 ’25. After this action, Monia Brett P now owns 180,980 shares of Ionis Pharmaceuticals Inc, valued at $4,525 using the latest closing price.
Monia Brett P, the Officer of Ionis Pharmaceuticals Inc, proposed sale 140 shares at $32.32 during a trade that took place back on Mar 11 ’25, which means that Monia Brett P is holding shares at $4,525 based on the most recent closing price.
Stock Fundamentals for IONS
Current profitability levels for the company are sitting at:
- -0.67 for the present operating margin
- 0.97 for the gross margin
The net margin for Ionis Pharmaceuticals Inc stands at -0.64. The total capital return value is set at -0.18. Equity return is now at value -93.03, with -15.13 for asset returns.
Based on Ionis Pharmaceuticals Inc (IONS), the company’s capital structure generated 0.71 points at debt to capital in total, while cash flow to debt ratio is standing at -0.35. The debt to equity ratio resting at 2.41. The interest coverage ratio of the stock is -5.53.
Currently, EBITDA for the company is -475.08 million with net debt to EBITDA at -3.28. When we switch over and look at the enterprise to sales, we see a ratio of 8.94. The receivables turnover for the company is 7.65for trailing twelve months and the total asset turnover is 0.23. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.47.
Conclusion
To sum up, Ionis Pharmaceuticals Inc (IONS) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
